📰 Dose Management News

Page 5 - Dose Management News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Dose Management. Real-time updates on events, politics, business and more.

FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease

March 6, 2023

06.03.2023 - Confirmatory Phase 3 Clarity AD data to be evaluated by FDA in determining whether to convert accelerated approval of LEQEMBI to a traditional approval Priority Review accelerates FDA review time with a Prescription Drug User Fee Act ...

New Zealand United Kingdom United States Haruo Naito Christophera Viehbacher Mike Hencke

Source: wallstreet-online.de

FDA accepts sBLA for traditional approval of LEQEMBI (lecanemab-irmb) for the treatment of Alzheimer's disease and grants Priority Review: BioArctic

March 6, 2023

STOCKHOLM, March 6, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai's

Uppsala Lan Oskar Bosson Dennis Riedl Uppsala University Vp Communications National Institutes Of Health

Source: finanznachrichten.de

FDA accepts sBLA for traditional approval of LEQEMBI™ (lecanemab-irmb) for the treatment of Alzheimer's disease and grants Priority Review: BioArctic

March 6, 2023

/PRNewswire/ -- BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the U.S. Food and Drug Administration (FDA) has accepted...

Uppsala Lan Oskar Bosson Uppsala University Vp Communications National Institutes Of Health National Institute On

Source: prnewswire.com

Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan

January 16, 2023

Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan - read this article along with other careers information, tips and advice on BioSpace

United Kingdom United States Haruo Naito Charles Weissmann Walter Gilbert Heinz Schaller

Source: biospace.com

EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN EUROPE

January 11, 2023

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...

New Zealand United States United Kingdom Haruo Naito Charles Weissmann Walter Gilbert

Source: prnewswire.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN EUROPE

January 10, 2023

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...

New Zealand United States United Kingdom Haruo Naito Charles Weissmann Walter Gilbert

Source: prnewswire.com

Community Scoop » FDA Approves LEQEMBI (lecanemab-irmb) Under The Accelerated Approval Pathway For The Treatment Of Alzheimer's Disease

January 9, 2023

Scoop Community provides New Zealand Community news and views

United Kingdom Haruo Naito Christophera Viehbacher Centers For Medicare Eisai Co Ltd Eisai Patient Assistance Program

Source: scoop.co.nz

FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

January 7, 2023

FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease - read this article along with other careers information, tips and advice on BioSpace

New Zealand United Kingdom United States Haruo Naito Charles Weissmann Walter Gilbert

Source: biospace.com

EISAI'S APPROACH TO U.S. PRICING FOR LEQEMBI™ (LECANEMAB), A TREATMENT FOR EARLY ALZHEIMER'S DISEASE, SETS FORTH OUR CONCEPT OF "SOCIETAL VALUE OF MEDICINE" IN RELATION TO "PRICE OF MEDICINE"

January 6, 2023

/PRNewswire/ -- Based on hhc (human health care) concept, our corporate philosophy, Eisai is committed to improve patients health outcomes and quality of life,...

United States Comunidad Autonoma De Cataluna Alzheimers Dement Libby Holman Evidence Forum Eisai Inc

Source: prnewswire.com